Ascendiant analyst Edward Woo maintained a Buy rating on Imac Holdings (BACK – Research Report) on April 5 and set a price target of $1.50. The company’s shares closed yesterday at $0.13.
Woo covers the Healthcare sector, focusing on stocks such as BioSig Technologies, Vivos Therapeutics, and Biolase. According to TipRanks, Woo has an average return of -1.7% and a 41.36% success rate on recommended stocks.
Imac Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $1.50.
See today’s best-performing stocks on TipRanks >>
Based on Imac Holdings’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $3.79 million and a GAAP net loss of $6.33 million. In comparison, last year the company earned a revenue of $4.37 million and had a GAAP net loss of $2.88 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IMAC Holdings, Inc. provides medical services through integrated medicine and chiropractic regeneration centers. Its services include medical treatments, regenerative medicine, physical medicine, physical therapy, spinal decompression and chiropractic manipulation. The company was founded by Matthew C. Wallis, Jason William Brame and Jeffrey S. Ervin in August 2000 and is headquartered in Brentwood, TN.
Read More on BACK:
- IMAC Holdings Reports Year End 2022 Financial Results and Corporate Update
- IMAC Holdings and Brain Scientific Announce a Strategic Merger to Create Synergistic End-To-End Neurological Solution
- IMAC Holdings, Brain Scientific announce strategic merger
- IMAC Holdings, Brain Scientific announce merger of equals
- IMAC Holdings, Inc announces the sale of The BackSpace
